Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjogren's Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Iscalimab (Primary) ; Iscalimab (Primary)
- Indications Sjogren's syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 09 Nov 2021 Results assessing possible options for alternative responder definitions that indicate the optimal balance of sensitivity and specificity from dour trials ((NCT02962895, NCT02775916; NCT02291029; NCT02149420) presented at the ACR Convergence 2021
- 15 Jun 2019 Results (n=25) testing IV versus SC loading doses of iscalimab followed by SC maintenance dosing, presented at the 20th Annual Congress of the European League Against Rheumatism.
- 14 Feb 2019 This trial has been completed in the United Kingdom, according to European Clinical Trials Database.